March 24, 2021
1 min read
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
A new study confirms previous reports that lower vitamin D levels are linked to an increased risk of developing COVID-19, especially in black adults. It was the top story in endocrinology last week.
Another top story looked at an association between high HbA1c levels in children with type 1 diabetes and an increased risk of neurodevelopmental disorders, including ADHD and autism spectrum disorders.
Source: Adobe Stock
Read these and other top stories in endocrinology below:
Vitamin D Levels Linked to COVID-19 Risk for Black Adults
Black adults with adequate vitamin D levels were still significantly more likely to be positive for COVID-19 than black adults with vitamin D levels of at least 40 ng / ml, according to data from a single-center study. Continue reading.
High HbA1c levels in type 1 diabetes associated with an increased risk of neurodevelopmental disorders
Children with type 1 diabetes are at increased risk of developing neurodevelopmental disorders, according to a study published in Diabetologia, whereas children with high HbA1c levels are at higher risk. Continue reading.
The CV benefits of type 2 diabetes agents may extend to type 1, but more data is needed
Type 2 diabetes agents with proven cardiovascular benefits may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD. However, more robust data are needed for the type 1 population. Continue reading.
Insulinaemic and inflammatory diets increase the risk of type 2 diabetes for postmenopausal women
Postmenopausal women who eat a highly pro-inflammatory or hyperinsulinemic diet are at increased risk of developing type 2 diabetes, according to data on the Women’s Health Initiative published in Diabetes Care. Continue reading.
Zoledronic acid maintains BMD gains after combination therapy with teriparatide and denosumab
Short-term therapy with teriparatide plus denosumab with a single dose of zoledronic acid can prevent bone loss associated with stopping denosumab in postmenopausal women, according to a study published in the Journal of Bone and Mineral Research. Continue reading.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
